Thursday, February 03, 2022


Lockdowns only reduced COVID-19 mortality by .2%, study finds: 'Lockdowns should be rejected out of hand'

Lockdowns during the first COVID-19 wave in the spring of 2020 only reduced COVID-19 mortality by .2% in the U.S. and Europe, according to a Johns Hopkins University meta-analysis of several studies.

"While this meta-analysis concludes that lockdowns have had little to no public health effects, they have imposed enormous economic and social costs where they have been adopted," the researchers wrote. "In consequence, lockdown policies are ill-founded and should be rejected as a pandemic policy instrument."

The researchers – Johns Hopkins University economics professor Steve Hanke, Lund University economics professor Lars Jonung, and special advisor at Copenhagen's Center for Political Studies Jonas Herby – analyzed the effects of lockdown measures such as school shutdowns, business closures, and mask mandates on COVID-19 deaths.

"We find little to no evidence that mandated lockdowns in Europe and the United States had a noticeable effect on COVID-19 mortality rates," the researchers wrote.

The researchers also examined shelter-in-place orders, finding that they reduced COVID-19 mortality by 2.9%.

Studies that looked at only shelter-in-place orders found they reduced COVID-19 mortality by 5.1%, but studies that looked at shelter-in-place orders along with other lockdown measures found that shelter-in-place orders actually increased COVID-19 mortality by 2.8%.

The researchers concluded that limiting gatherings may have actually increased COVID-19 mortality.

"[Shelter-in-place orders] may isolate an infected person at home with his/her family where he/she risks infecting family members with a higher viral load, causing more severe illness," the researchers wrote.

"But often, lockdowns have limited peoples’ access to safe (outdoor) places such as beaches, parks, and zoos, or included outdoor mask mandates or strict outdoor gathering restrictions, pushing people to meet at less safe (indoor) places."

The researchers also examined studies that focused on specific lockdown measures and found that the only intervention that reduced COVID-19 mortality was the closure of non-essential businesses, which reduced mortality by 10.6%, but this effect was likely driven by the closure of bars.

Researchers also pointed out other unintended consequences of lockdowns, such as rising unemployment, reduced schooling, an increase in domestic violence incidents, and surging drug overdoses.

From May 2020 to April 2021, the U.S. recorded 100,306 drug overdose deaths, a 28.5% increase from the 78,056 deaths that were recorded in the previous 12-month period, according to CDC data.

A study from the National Commission on COVID-19 and Criminal Justice last year found that domestic violence incidents increased 8.1% in the U.S. after lockdown orders were issued.

About 97% of U.S. teachers said that their students have experienced learning loss during the coronavirus pandemic, according to a Horace Mann survey last year.

The unemployment rate peaked nationwide at 14.8% in April 2020, but declined to 3.9% in December, which is still slightly higher than the 3.5% rate it was at in February 2020.

"These costs to society must be compared to the benefits of lockdowns, which our meta-analysis has shown are marginal at best," the researchers in the Johns Hopkins University study wrote.

"Such a standard benefit-cost calculation leads to a strong conclusion: lockdowns should be rejected out of hand as a pandemic policy instrument."

President Biden has pledged to focus on testing and vaccinations to mitigate the spread of COVID-19 instead of the lockdowns that characterized the earlier part of the pandemic.

"It doesn’t include shutdowns or lockdowns, but widespread vaccinations and boosters and testing a lot more," Biden said in December about his winter plans for fighting the pandemic.

Several cities and states around the country still have mask mandates, remote learning, and other measures in place.

**********************************************

New Study on Ivermectin ‘Should Convince Any Naysayer’: Dr. Pierre Kory

So why has Ivermectin been officially scorned? No mystery: Trump recommended it

A recently published study indicating the anti-parasitic ivermectin worked well as a prophylactic against the virus that causes COVID-19 should help sway critics of the drug, according to Dr. Pierre Kory, president of the Front Line COVID-19 Critical Care Alliance (FLCCC).

“That should convince any naysayer,” Kory told The Epoch Times’ “American Thought Leaders.” “What they found was astounding.”

The Brazilian city of ItajaĆ­ launched a program that gave ivermectin to any residents that wanted any. The period that was studied was from July 7, 2020, to December 2, 2020.

Researchers found that the program, which had over 100,000 residents participate, was linked to a 44 percent drop in COVID-19 cases.

Approximately 3.7 percent of ivermectin users contracted the illness during the trial period, compared to 6.6 percent of residents who didn’t take the drug.

The program was also associated with a statistically significant decrease in hospitalization and mortality.

The peer-reviewed study was published in Cureus on Jan. 15.

“Ivermectin MUST be considered as an option, particularly during outbreaks,” Dr. Flavio Cadegiani, one of the study’s authors and a founding member of FLCCC, told The Epoch Times in an email.

FLCCC focuses on early treatment of COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. The group has recommended ivermectin since early 2020.

Kory said the lack of reporting on the study despite it being peer-reviewed highlights how some scientific developments are ignored by many media outlets and scientists.

“You would think this would lead major headlines everywhere. And yet, nothing. And this is not new, this censorship of this highly effective science and evidence around repurposed drugs. The censoring of it, it’s not new, it’s just getting more and more absurd. And it has to stop,” he said.

Studies on ivermectin against COVID-19 have shown mixed results, with some being associated with no or little benefit and others suggesting a strong benefit. It’s been widely used in India and other countries as a preventative measure, but in the United States and much of Europe many official health care bodies recommend against its use or do not endorse it.

Ivermectin has been approved for certain uses by the Food and Drug Administration, but not for use against COVID-19. That means doctors can prescribe it off-label.

The National Institutes of Health’s COVID-19 treatment guidelines panel currently says that there is not enough evidence to advise either for or against using ivermectin to treat COVID-19. It does not address its potential use as a prophylactic.

While the new study was celebrated by some, others questioned the findings and pointed out that the conflicts of interest disclosures show both Cadegiani and another author have received funding from or contracted with Vitamedic, a company that manufactures ivermectin.

Gideon Meyerowitz-Katz, an Australian epidemiologist, for instance, called it “a fairly simple example of observational research that you’d do on routine medical data” but alleged the controls for confounding factors such as occupation and risk factors were “pretty inadequate given the purpose.”

Cadegiani said the criticism was unfounded, saying he wasn’t convinced before the study that ivermectin would work as a preventative medicine and that researchers controlled for “all relevant factors,” including comorbidities, age, sex, and race.

“Their inability to focus on the data provided by the study itself is … proof of the extreme high quality of the study,” the doctor said, adding later that “To us, this is the best observational study on COVID-19 to date, with a power almost equivalent to a huge randomized clinical trial.”

The researchers plan on publishing multiple additional papers regarding the program, including papers on the biochemical effects of ivermectin and the effectiveness of the drug in preventing hospitalization.

*********************************************

Japanese firm says ivermectin shows ‘antiviral effect’ against Covid-19

The controversial drug ivermectin showed an “antiviral effect” against Omicron and other coronavirus variants in joint non-clinical research, a Japanese drug company said on Monday.

Trading and pharmaceutical company Kowa Co Ltd, which has been working with Tokyo’s Kitasato University testing the drug as potential treatment for Covid-19, did not provide further details, Reuters reported.

Ivermectin has been popularised as a Covid-19 treatment by some doctors and the likes of podcast host Joe Rogan, even as health authorities and the drug’s manufacturer Merck warn against its use, citing lack of evidence that it works against the virus.

A clinical trial being run in the UK by Oxford University, announced in June 2021, is ongoing.

The Oxford researchers told Reuters on Monday that they did not want to comment until they have results to report.

Ivermectin first began to be touted as a therapeutic for Covid-19 in early 2020 after scientists in Melbourne found it could inhibit SARS-CoV-2 in the lab in high doses.

“It was enthusiastically adopted by some clinicians and healthcare systems before any significant human trials were conducted, and subsequent trials have been largely small and conflicted,” Associate Professor Justin Denholm, principal investigator on the Australasian Covid-19 Trial (ASCOT), wrote in August 2021.

“Now, a number of retrospective reviews and meta-analyses have been released, which mostly agree that studies to date have generally been of low quality and high risk of bias, but offering different conclusions about whether ivermectin improves outcomes.”

*********************************************

Also see my other blogs. Main ones below:

http://edwatch.blogspot.com (EDUCATION WATCH)

http://antigreen.blogspot.com (GREENIE WATCH)

http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)

http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS)

http://snorphty.blogspot.com/ (TONGUE-TIED)

*************************************

No comments: